Yuhan Corporation
000100
Rang in Aktien
#3832
Yuhan Corporation, a prominent South Korean pharmaceutical firm established in... Yuhan Corporation, a prominent South Korean pharmaceutical firm established in 1926 and headquartered in Seoul, specializes in the research, development, and manufacture of active pharmaceutical ingredients (APIs) and intermediates for both domestic and international markets. Its extensive product portfolio encompasses a wide array of prescription pharmaceuticals (ETC), addressing therapeutic areas such as cardiovascular, alimentary, genito-urinary, metabolic, respiratory, allergy, and neurological systems, alongside anti-infectives, anti-cancer treatments, and hormonal therapies. Notable offerings include Revanex, an acid pump antagonist designed for treating peptic ulcers and gastritis-related mucosal injury. Beyond prescription drugs, Yuhan Corporation provides a diverse range of over-the-counter (OTC) medications, including vitamins, mineral supplements, hepatopathy treatments, tonics, and drugs for respiratory, alimentary, dermatological, and pain relief applications. The company also extends its reach into consumer health and household goods, producing items like bleaches, detergents, pesticides, and oral care products. Further diversifying its operations, Yuhan is involved in the dental sector, supplying implants, equipment, consumables, and dental care solutions, and manufactures veterinary medical supplies for livestock, aquatic species, and companion animals. Additionally, it offers contract manufacturing services to other businesses.
Aktienkurs
$63.22
Marktkapitalisierung
$4.27B
Veränderung (1 Tag)
-3.12%
Veränderung (1 Jahr)
-23.57%
Land
KR
Handel Yuhan Corporation (000100)
Kategorie
Healthcare
Gewinn für Yuhan Corporation (000100)
Gewinn im Jun 2026 TTM: $205.87M
Laut den aktuellen Finanzberichten von Yuhan Corporation betragen die aktuellen Gewinne des Unternehmens $205.87M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $41.79M, ein Rückgang im Vergleich zu dem Gewinn im Jahr 2023, der $104.14M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Yuhan Corporation von 2007 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $205.87M | 33.56% |
| 2025 | $154.14M | 268.88% |
| 2024 | $41.79M | -59.88% |
| 2023 | $104.14M | 38.44% |
| 2022 | $75.22M | -29.06% |
| 2021 | $106.03M | -52.01% |
| 2020 | $220.97M | 364.61% |
| 2019 | $47.56M | -40.76% |
| 2018 | $80.28M | -40.96% |
| 2017 | $135.98M | -19.98% |
| 2016 | $169.93M | 18.62% |
| 2015 | $143.25M | 35.02% |
| 2014 | $106.09M | 4.27% |
| 2013 | $101.75M | 1.19% |
| 2012 | $100.55M | 9.06% |
| 2011 | $92.20M | -27.70% |
| 2010 | $127.53M | 8.26% |
| 2009 | $117.80M | 4.84% |
| 2008 | $112.36M | 0.30% |
| 2007 | $112.02M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $3.62B | 1,657.37% |
DE
|
|
| $3.40B | 1,553.97% |
DE
|
|
| $1.72B | 737.24% |
JP
|
|
| $930.30M | 351.89% |
CH
|
|
| $1.69B | 722.21% |
IN
|
